Dr Wang is a computational biologist. He was trained as a computer scientist initially in China. Impressed by the beauty of Life Sciences and importance of cancer research, he decided to dedicate to the interdisciplinary field of computational biology. Dr Wang pursued his PhD at the University of Cambridge Department of Oncology and Cancer Research UK Cambridge Institute, where his research was concerned with how to infer intracellular signalling pathways from phenotyping screens. In collaboration with experimental oncologists, he also identified three molecularly distinct colon cancer subtypes using an unsupervised classification approach. From 2013 to 2015, Dr Wang did his postdoc training at Harvard Medical School Department of Biomedical Informatics, where he learned advanced techniques in next-generation sequencing data analysis.
- Cancer genomics
- Prognostic and predictive biomarkers
- Regulatory networks
- Therapeutic targets
- Bioinformatic tools
Dr Wang's major research interest is to better understand the biology underlying cancer using quantitative approaches. Especially, he has more passion in projects that bridge basic biological studies and clinical research. He has rich experience in integrative analysis of multilevel (epi)genomic data and clinical outcomes for dissecting cancer heterogeneity. Currently, his research consists of four parts:
- identifying and characterizing molecularly distinct cancer subtypes that are in relation to clinical responses;
- identifying prognostic and predictive cancer biomarkers that are more accessible in the clinic;
- identifying potential therapeutic targets using network-based approaches;
- developing bioconductor packages and web tools for analyzing next-generation sequencing data (SPP2), high-throughput screens (HTSanalyzeR), etc.